Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | THRA | P10827 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.37 |
| ▸ | RHEB | Q15382 | 3/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.33 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5411581 | 0.88 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19THRATHRB | |
| SCHEMBL5364856 | 0.87 | CYP3A4 (0.47) | CYP3A4CYP2C9CYP2C19THRATHRB | |
| SCHEMBL5370372 | 0.86 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP2C19THRATHRB | |
| SCHEMBL5373847 | 0.86 | THRA (0.44) | CYP3A4CYP2C9CYP2C19THRATHRB | |
| SCHEMBL5368441 | 0.86 | CYP3A4 (0.58) | CYP3A4CYP2C9CYP2C19THRATHRB | |
| SCHEMBL14570716 | 0.85 | CYP3A4 (0.60) | CYP3A4CYP2C9CYP2C19THRATHRB | |
| SCHEMBL5368884 | 0.83 | CYP3A4 (0.68) | CYP3A4CYP2C9CYP2C19THRATHRB | |
| SCHEMBL5368877 | 0.82 | CYP3A4 (0.70) | CYP3A4CYP2C9CYP2C19RHEBMAPK8 | |
| SCHEMBL14559741 | 0.80 | CYP3A4 (0.75) | CYP3A4CYP2C9CYP2C19THRATHRB | |
| SCHEMBL5373843 | 0.80 | CYP3A4 (0.65) | CYP3A4CYP2C9CYP2C19THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-7189718-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189718-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189718-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-03-13 | — | — | US | disclosed |